Circ Cardiovasc Interv

Slides:

Advertisements

Similar presentations

Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.

Advertisements

Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early and long-term clinical outcomes associated.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Prevalence and Clinical Implications of Newly Revealed,

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Long-Term Clinical Results Following Stenting of.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Volume 385, Issue 9985, Pages (June 2015)

Previous coronary stents do not increase early and long-term adverse outcomes in patients undergoing off-pump coronary artery bypass grafting: A propensity-matched.

Copyright © 2006 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.

Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.

Circ Cardiovasc Interv

Plasma Vitamin C, but Not Vitamin E, Is Associated With Reduced Risk of Heart Failure in Older MenClinical Perspective by Sasiwarang Goya Wannamethee,

Circ Cardiovasc Interv

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Circ Cardiovasc Interv

Circ Cardiovasc Qual Outcomes

Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,

Circ Cardiovasc Imaging

Circ Cardiovasc Interv

Circ Cardiovasc Interv

Catheter-Based Treatment of Coronary Artery Disease

Baseline characteristics of patients

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

The impact of incomplete revascularization and angiographic patency on midterm results after off-pump coronary artery bypass grafting Jota Nakano, MD,

Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome Michael J. Mack, MD, Adrian P. Banning,

Peter K. Smith, MD, Michel Carrier, MD, John C

The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Leonardo P. de Carvalho et al. BTS 2018;3:

Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Volume 385, Issue 9985, Pages (June 2015)

The influence of bilateral internal mammary arteries on short- and long-term outcomes: A propensity score matching in accordance with current recommendations

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Neal A. Chatterjee et al. JCHF 2014;2:

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Nat. Rev. Cardiol. doi: /nrcardio

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Long-term survival after vascular surgery: Specific influence of cardiac factors and implications for preoperative evaluation Martin R. Back, MD, Fabian.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Stent Versus Off-Pump Coronary Bypass Grafting in the Second-Generation Drug- Eluting Stent Era Gijong Yi, MD, PhD, Hyun-Chel Joo, MD, Young-Nam Youn,

The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery Mark A. Hlatky, MD, David Shilane, PhD, Derek.

Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Baseline Characteristics of the Patients – Part I

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Kaplan-Meier survival estimates for major cardiovascular events.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Javier Escaned et al. JCIN 2018;11:

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Left Ventricular Mass at MRI and Long-Term Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA) Left ventricular hypertrophy.

A and B, The ROC curves analyzing the sensitivity and specificity of the WHO grading system (I-IV) for the 1-year survival (A) and recurrence (B) show.

Transcatheter aortic valve implantation versus surgical aortic valve replacement: A propensity score analysis in patients at high surgical risk Lenard.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Circ Cardiovasc Interv A New Tool for the Risk Stratification of Patients With Complex Coronary Artery DiseaseClinical Perspective by Scot Garg, Giovanna Sarno, Hector M. Garcia-Garcia, Chrysafios Girasis, Joanna Wykrzykowska, Keith D. Dawkins, Patrick W. Serruys, and Circ Cardiovasc Interv Volume 3(4):317-326 August 17, 2010 Copyright © American Heart Association, Inc. All rights reserved.

Kaplan Meier curves for death (A), repeat revascularization (B), myocardial infarction (MI) (C), and major adverse cardiovascular and cerebrovascular events (MACCE) (D) at 1800-day follow-up stratified accord to CSS tertile. Kaplan Meier curves for death (A), repeat revascularization (B), myocardial infarction (MI) (C), and major adverse cardiovascular and cerebrovascular events (MACCE) (D) at 1800-day follow-up stratified accord to CSS tertile. Scot Garg et al. Circ Cardiovasc Interv. 2010;3:317-326 Copyright © American Heart Association, Inc. All rights reserved.

ROC curve for the SYNTAX score, ACEFSCr, and CSS for mortality (A) and MACCE (B). ROC curve for the SYNTAX score, ACEFSCr, and CSS for mortality (A) and MACCE (B). The use of the CSS leads to an improvement in the C-statistic for both outcomes. Scot Garg et al. Circ Cardiovasc Interv. 2010;3:317-326 Copyright © American Heart Association, Inc. All rights reserved.

Kaplan-Meier curve showing the 5-year mortality (A) and MACCE-free survival (B) stratified according to tertiles of the CSS, Mayo Clinic Risk Score (MCRS), Additive euroSCORE (EUROADD) and Logistic euroSCORE (EUROLOG). Kaplan-Meier curve showing the 5-year mortality (A) and MACCE-free survival (B) stratified according to tertiles of the CSS, Mayo Clinic Risk Score (MCRS), Additive euroSCORE (EUROADD) and Logistic euroSCORE (EUROLOG). No significant difference was observed between outcomes in Tertiles 1 and 2 (probability values not shown). *P (log-rank) values. Scot Garg et al. Circ Cardiovasc Interv. 2010;3:317-326 Copyright © American Heart Association, Inc. All rights reserved.

ROC curve for mortality (A) and MACCE (B) at 5-year follow-up for different risk scores. *P<0.001, †P<0.05, ¶P<0.01. ROC curve for mortality (A) and MACCE (B) at 5-year follow-up for different risk scores. *P<0.001, †P<0.05, ¶P<0.01. Scot Garg et al. Circ Cardiovasc Interv. 2010;3:317-326 Copyright © American Heart Association, Inc. All rights reserved.